Need to keep on high of the science and politics driving biotech immediately? Enroll to get our biotech publication in your inbox.
Hello, biotech pals. As we gear up for ASCO, we cogitate on some attention-grabbing questions. As an illustration: Gene remedy carries nice potential to treatment sure types of congenital deafness, however does the group truly need that? Additionally, we see a confirmatory trial fail in Duchenne, and extra.
The necessity-to-know this morning
- An experimental drug from Insmed efficiently decreased lung issues amongst sufferers with an airway illness in a carefully watched Section 3 trial, sending the corporate’s share value hovering early this morning.
- In search of to construct up its pharma enterprise, the Japanese conglomerate Asahi Kasei is shopping for Swedish biotech Calliditas Therapeutics in a virtually $1.1 billion money deal.
- Agios Prescribed drugs introduced a $905 million purchase agreement with Royalty Pharma for rights to royalties on gross sales of the most cancers drug vorasidenib.
- An inhaled, mRNA-based drug from Arcturus Therapeutics improved lung function in sufferers with cystic fibrosis, based on a preliminary outcomes from a Section 1 research.
- Johnson & Johnson is paying $1.25 billion to acquire an experimental bispecific antibody beneath improvement for atopic dermatitis from privately held Numab Therapeutics.
ASCO research to look at
The annual assembly of ASCO begins later this week, and the glut of latest information generally is a bit overwhelming. So we’re highlighting some research which are of explicit curiosity, as we await information from STAT’s Adam Feuerstein, Matthew Harper, and Angus Chen, who will likely be on website in Chicago. (Join our day by day “ASCO in 30 seconds” publication right here.)
We’re to be taught extra about some spectacular CAR-T outcomes from AstraZeneca and Chinese language associate AbelZeta in sufferers with superior liver most cancers. There’s additionally information from Australia displaying that clinicians could in a position to bypass chemotherapy in some sufferers with stage 2 colorectal most cancers. We’re intrigued by an AI-based affected person navigator that helps sufferers entry colonoscopy. And extra!
Learn extra.
Will gene remedy ‘endanger’ the deaf group?
The deaf group is carefully knit and identified for its vibrance. However now that gene therapies are being launched that may treatment sure types of congenital listening to loss, an previous query is reemerging: Do deaf folks need a “treatment?”
Present gene therapies solely exist for a small slice of the deaf inhabitants, however some specialists wager they might in the end be utilized in maybe half of all congenitally deaf folks. And that considerations some bioethicists and members of the group.
“For the signing and deaf group to live on, we have to have a essential mass of individuals,” one deaf philosophy professor informed STAT’s Timmy Broderick. “What occurs if the variety of deaf folks dwindles to a low sufficient level? What’s the affect of that expertise, then?”
Learn extra.
A Duchenne confirmatory trial fails for exon-skipper
Duchenne muscular dystrophy drug Viltepso didn’t meet its major endpoint in a confirmatory trial. Though the kids who got the medication might get up sooner from the ground on the finish of the research, the kids within the placebo arm of the trial might achieve this as properly — with no statistically vital distinction between the teams.
The therapy, made by Japanese drugmaker Nippon Shinyaku, is a part of the controversial group of medication known as exon-skippers. They’re designed to extend the quantity of dystrophin proteins in these sufferers, who lack the power to supply them on their very own. Sarepta’s exon-skipper drug, Exondys 51, was first accredited in 2016 because of tireless lobbying efforts from dad and mom of kids with the illness — however has but to finish confirmatory trials for the drug.
Learn extra.
Merus drug, with immunotherapy, boosts tumor response in sufferers with head and neck most cancers
Merus mentioned this morning that the mixture of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of sufferers with head and neck most cancers, based on an interim evaluation of an ongoing mid-stage medical trial.
The brand new efficacy outcomes, derived from a bigger variety of sufferers, look just like an preliminary disclosure made final week that triggered a 36% enhance in Merus’ inventory value.
Petosemtamab has generated appreciable consideration, notably from biotech buyers, on account of its potential to enhance the therapy of head and neck most cancers, the sixth most-common most cancers worldwide. Presently, sufferers with metastatic however newly recognized head and neck most cancers are usually handled with Keytruda, the anti-PD-1 immunotherapy made by Merck, or a mix of Keytruda and chemotherapy.
Learn extra.
New financings on our radar
Simply highlighting just a few attention-grabbing fundraises from the previous week:
Halda Therapeutics is two-thirds of the way in which into elevating a $36 million round, regulatory filings present. The Yale spinout is creating what it has trademarked “RIPTAC” bifunctional molecules for most cancers, which use ligands to hyperlink proteins collectively to focus on tumor cells and “hold and kill” them. Halda got here out of stealth a yr in the past with $76 million in financing.
We’ve additionally discovered of a $22 million Collection A spherical from Valar Labs, which makes use of AI to foretell responses to most cancers therapies. The funding was co-led by Andreessen Horowitz and DCVC; earlier this month, Valar released data displaying that its histology check might predict a affected person’s response to BCG in high-risk non-muscle invasive bladder most cancers.
Some bigger rounds we famous: Pheon Therapeutics raised a $120 million Series B for its antibody-drug conjugate medication for most cancers. And one other weight problems participant, SixPeaks Bio, got here out of stealth with $110 million in funding — with doubtlessly $80 million from AstraZeneca.
Extra reads
- Takeda shedding 641 employees in Massachusetts, Boston Globe
- FDA panel votes in opposition to Novo Nordisk’s weekly insulin in sort 1 diabetes sufferers, Reuters
- Even after sharp gross sales drop, Pfizer sees vibrant aspect with precedence overview voucher from Paxlovid approval, FiercePharma
